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ABSTRACT
Tuberculosis (TB) is one of the top 10 causes of death worldwide. Multidrug-resistant tuberculosis (MDR-TB) occurs when at the minimum 
there is resistance to isoniazid and rifampin. Prevention of new infections of Mycobacterium tuberculosis and progression to TB disease is 
critical to reduce the burden and mortality of this disease. We present the case of a 73-year-old human immunodeficiency virus (HIV)-
negative female who presented with cervical lymphadenopathy and who was diagnosed with MDR-TB.
LEARNING POINTS
• Tuberculosis is one of the most important causes of morbidity and mortality worldwide and approximately a quarter of the world’s 
population is estimated to be latently infected by Mycobacterium tuberculosis.
• Multidrug-resistant tuberculosis lymphadenitis is a rare manifestation of the disease in Portugal.
• With the advent of multidrug-resistant tuberculosis, disease surveillance by the government should be intensified, with the aim of 
national and global TB control, focusing on prevention.
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CASE DESCRIPTION
A 73-year-old woman who had recently arrived from Cape Verde presented a slow-growth cervical mass with 4 weeks of evolution. In the 2 
previous weeks, she reported complaints of local heat, oedema and flushing, associated with pruritus. She had a dry cough and sweating but 
no fever and anorexia. She had lost weight quantified at approximately 15% of her body mass over the previous 8 months. The patient denied 
other respiratory, gastrointestinal and genitourinary symptoms.
At admission, the patient showed flushed suprasternal and supraclavicular masses, painful to palpation, with signs of fluctuation (Fig. 
1). Numerous lymph nodes were also palpable in the neck. Viral serologies were negative, including for HIV. Blood cultures and sputum 
cultures were negative. A chest x-ray did not show evidence of cavitation. Ultrasound of soft parts of the neck described a non-pure, poorly 
circumscribed collection of anfractuous borders that reached the deep planes, in the anterior and inferior cervical region, with other images 
of an identical nature in the supraclavicular topography. Neck and chest computed tomography (CT) scanning showed the images seen in 
the ultrasound, attributing these with a cystic component; the tracheobronchial tree was permeable, with no evidence of alterations in the 
pulmonary parenchyma. The fine needle aspiration (FNA) procedure was performed with sample collection for microbiological study and a 
sample was sent for pathologic anatomy assessment. A probable diagnosis of peripheral tuberculous lymphadenitis or scrofuloderma was 
assumed and a skin biopsy was performed; the Mantoux test was reactive, 30 mm (Fig. 2).
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Figure 1. Cervical mass affecting bilateral supraclavicular topography at admission Figure 2. Positive Mantoux test (30 mm)
Given the diagnostic presumption, the patient began empiric anti-tuberculostatic quadruple therapy (isoniazid, rifampin, pyrazinamide 
and ethambutol). Meanwhile, echo-guided percutaneous drainage was performed, with an output of thick viscid pus, of which polymerase 
chain reaction (PCR) analysis for Mycobacterium tuberculosis was positive. PCR analysis for non-tuberculous mycobacterium, RNA 16S and 
panfungal PCR were negative. PCR testing for Mycobacterium tuberculosis in medullary blood was also positive.
The patient evolved favourably, continuing out-patient treatment for disseminated tuberculosis, while the cervical masses progressed with 
suppuration and later cicatrization (Fig. 3). 
Figure 3. Two months after admission, the cervical mass progressed with suppuration 
and cicatrization 
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Cultural examination of the pus yielded Mycobacterium tuberculosis and the drug susceptibility test (DST) showed multidrug-resistant 
tuberculosis (MDR-TB). The treatment was switched to pyrazinamide, ethionamide, clofazimine, moxifloxacin and amikacin. The patient was 
subsequently referred for close follow-up to the local department of health and was scheduled to undergo therapy for at least 18 months.
DISCUSSION
Tuberculosis (TB) is 1 of the most important causes of morbidity and mortality worldwide, caused by various strains of mycobacteria, usually 
Mycobacterium tuberculosis. Approximately 23% of the world’s population is estimated to be latently infected by Mycobacterium tuberculosis 
(LTBI). Diagnostic and therapeutic challenges constitute management problems as TB mimics other pathological processes and yields 
inconsistent clinical and laboratory findings [1, 2]. In 2017, there were approximately 10 million new cases of TB around the world with 3.5% 
due to MDR-TB, with 18% of MDR-TB occurring in previously treated cases [1]. In Portugal, during the last 10 years, the incidence of TB has 
decreased by approximately 40%, with a low prevalence (<20 cases/100,000 population) since 2015. In 2017, 1,741 cases were notified, of 
which 1,697 were new cases and 12 were multidrug resistant (0.7%) [2].
Tuberculous lymphadenitis (TBL) is among the most frequent presentations of extrapulmonary TB in countries with a low prevalence of TB, 
while in high prevalence areas, the TBL incidence is second to that of tuberculous pleuritis[1]. TBL has a female-to-male ratio of 1.4:1, while 
pulmonary TB is more common among men[1,3]. The peak age for TBL ranges from 30 to 40 years. TBL located in the cervical region is known 
as peripheral tuberculous lymphadenitis or scrofula and it is usually due to reactivation of disease by haematogenous spread from a site 
during primary TB infection, perhaps years earlier; however, miliary dissemination with prominent lymph node involvement in the setting 
of primary infection can also occur. A definitive diagnosis is made by culture or nucleic acid amplification of Mycobacterium tuberculosis in 
an affected lymph node, but demonstration of acid-fast bacilli and granulomatous inflammation may also be helpful. FNA is less invasive 
and may be useful for diagnosis, but excisional biopsy has the highest sensitivity (80%) and may produce a more rapid and favourable 
symptomatic response[3]. The most common presentation of TBL is an isolated, chronic non-tender lymphadenopathy in the anterior or 
posterior cervical triangles, that can be present for up to 12 months before diagnosis and can be complicated by ulceration, fistula or abscess 
formation. Systemic symptoms are not common. Physical examination reveals a firm, discrete mass or matted nodes fixed to surrounding 
structures and the skin may be indurated. The differential diagnosis is extensive and includes malignancy, Kikuchi disease, sarcoidosis and 
other infections such as non-tuberculous mycobacteria, cat scratch disease, fungal infection and bacterial adenitis[3, 4].
Before the era of antibiotics, in the Middle Ages, it was believed that a touch from royalty could heal skin; scrofula was known as ‘king's 
evil’. Patients rarely died from it and were unlikely to progress to pulmonary TB. However, there is a lack of information in the literature 
regarding multidrug resistance in scrofula. However, it seems that nothing has changed with respect to the natural history of the disease and 
its association with pulmonary TB. In addition, although scrofula is known to have a good prognosis, our patient had a disseminated MDR-TB 
lymphadenitis, which in her home country could progress into pulmonary TB, with high risk of transmission and death.
Thus, MDR-TB lymphadenitis is a rare manifestation of significant public health concern and it is an atypical presentation of the disease in 
Portugal, being more common in TB-endemic regions. In the present day, with the advent of increased globalization and immigration, cases 
of TB and drug-resistant TB may continue to rise and represent a threat to global TB control. The main causes of the increasing spread of 
resistant TB strains are limited resources with weak medical systems, poverty, amplification of resistance through incorrect treatment and 
ongoing transmission in most vulnerable communities. Ultimately, for long-range success, policies that intensify disease surveillance efforts, 
particularly in high-risk populations, should be created and implemented[1, 5]. Drug-resistant TB has widespread health, social and economic 
implications, as its emergence threatens gains already made with respect to national and global TB control. Public health systems may need 
to be reinforced to ensure closely monitored treatment (directly observed therapy, DOT), to prevent the development of resistant forms of 
the disease. Thus, urgent action is required to improve the coverage and quality of diagnosis, treatment and care for people with MDR-TB[5].
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